Webster Bank N. A. trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 18.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,509 shares of the biopharmaceutical company’s stock after selling 6,314 shares during the quarter. Webster Bank N. A.’s holdings in Bristol-Myers Squibb were worth $1,759,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Security Asset Management boosted its holdings in shares of Bristol-Myers Squibb by 20.3% in the first quarter. Security Asset Management now owns 9,230 shares of the biopharmaceutical company’s stock valued at $640,000 after acquiring an additional 1,558 shares in the last quarter. Richard P Slaughter Associates Inc increased its position in shares of Bristol-Myers Squibb by 3.5% during the 2nd quarter. Richard P Slaughter Associates Inc now owns 22,040 shares of the biopharmaceutical company’s stock valued at $1,409,000 after purchasing an additional 750 shares during the period. Talbot Financial LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth $4,482,000. Ethic Inc. lifted its holdings in shares of Bristol-Myers Squibb by 26.4% in the first quarter. Ethic Inc. now owns 121,524 shares of the biopharmaceutical company’s stock valued at $8,423,000 after buying an additional 25,385 shares during the period. Finally, Atlas Wealth LLC bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $276,000. 74.98% of the stock is owned by institutional investors and hedge funds.
Bristol-Myers Squibb Stock Up 0.2 %
BMY stock traded up $0.10 during midday trading on Tuesday, reaching $58.68. The company had a trading volume of 4,660,209 shares, compared to its average volume of 8,976,633. The company has a 50 day moving average of $61.62 and a two-hundred day moving average of $65.11. The company has a current ratio of 1.39, a quick ratio of 1.28 and a debt-to-equity ratio of 1.08. Bristol-Myers Squibb has a 1 year low of $58.33 and a 1 year high of $81.43. The company has a market capitalization of $122.59 billion, a P/E ratio of 15.58, a PEG ratio of 1.57 and a beta of 0.42.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the stock. HSBC began coverage on shares of Bristol-Myers Squibb in a research report on Friday, July 14th. They set a “reduce” rating and a $56.00 price objective for the company. Atlantic Securities decreased their price target on shares of Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, July 28th. Daiwa Capital Markets assumed coverage on Bristol-Myers Squibb in a research report on Wednesday, June 28th. They set an “outperform” rating and a $70.00 price objective for the company. Barclays decreased their target price on Bristol-Myers Squibb from $64.00 to $62.00 and set an “equal weight” rating on the stock in a report on Friday, July 28th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $70.67.
Insider Buying and Selling at Bristol-Myers Squibb
In other news, EVP Ann Powell sold 17,986 shares of the stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the transaction, the executive vice president now owns 27,868 shares of the company’s stock, valued at approximately $1,706,915. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Robert M. Plenge sold 732 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total transaction of $44,754.48. Following the completion of the transaction, the executive vice president now owns 6,584 shares of the company’s stock, valued at approximately $402,545.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ann Powell sold 17,986 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total value of $1,101,642.50. Following the completion of the sale, the executive vice president now directly owns 27,868 shares in the company, valued at approximately $1,706,915. The disclosure for this sale can be found here. Corporate insiders own 0.08% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
- Five stocks we like better than Bristol-Myers Squibb
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Hold-It-Forever AutoZone Pulls into Buy Zone
- What is Forex and How Does it Work?
- Virtual Riches: 3 Stocks Leading the VR Revolution
- What is the FTSE 100 index?
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.